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Table S1. Anticancer activity i.e. one-dose data for Benzothiazole-triazole hybrids retrieved from 
NCI database 
Cell Line                                                      Mean Growth percent 
     (4a ) (5a) (5b) (4b) (4c) (4d) (5c) (5d) (5e) (5f) 
Leukemia 
CCRF-CEM   97.53 103.39  97.10 99.95     100.65 99.73 
HL-60(TB)    99.41  97.05 97.67 99.01 98.78 99.76 97.39 98.11 100.28 97.57 
K-562   100.10 94.76 96.78 98.85 102.94 103.40 100.23 90.24 97.30 99.57 
MOLT   100.90 104.00 99.08 100.72 105.60 101.11 100.97 102.35 109.76 109.86 
RPMI-8226   94.32 107.09 95.72 104.78 95.34 98.00 98.74 100.33 106.11 114.31 
SR   96.21 100.05 91.37 95.19 109.51 105.34 104.25 99.06 99.57 106.74 
Non-Small Cell Lung Cancer 
A549/ATCC   106.31 97.15 103.71 98.98 105.08 100.06 100.85 104.02 102.80 99.86 
EKVX   94.06 94.13 91.48 104.19 94.86 98.74 102.71 92.51 94.85 101.96 
HOP-62   100.98 100.51 101.77 101.37 100.99 100.29 103.65 102.29 113.39 106.66 
HOP-92   102.44 105.96 106.90 113.47 107.42 105.93 103.60 101.85 114.81 113.12 
NCI-H226   102.77 103.21 103.98 105.19 98.93 102.16 101.68 100.92 101.64 104.48 
NCI-H23   96.65 101.29 97.03 100.52 99.88 96.52 101.16 100.12 102.91 108.79 
NCI-H460   104.23 106.33 104.28 104.38 101.22 101.67 103.48 102.81 107.71 109.28 
NCI-H522   97.92 93.74 92.52 89.39 97.81 90.05 95.33 94.50 96.78 92.19 
Colon Cancer 
COLO 205   111.39 111.48 109.30 108.02 110.76 105.84 109.41 107.57 112.53 109.56 
HCC-2998   108.72 109.28 102.79 108.56 105.00 115.24 104.66 109.53 106.50 109.79 
HCT-116   107.09 97.21 101.04 100.38 96.09 95.89 98.03 96.49 105.67 103.33 
HCT-15   102.74 105.01 104.66 105.66 107.13 104.31 105.42 102.21 109.68 108.98 
HT29   117.78 99.48 106.33 106.51 103.46 96.05 106.18 106.32 106.76 105.35 
KM12   105.95 107.16 107.67 101.87 103.17 104.94 102.68 103.16 111.54 108.08 
SW-620   100.31 106.40 98.53 102.55 95.84 95.96 95.20 101.12 107.64 112.89 
CNS Cancer 
SF-268   95.83 99.00 98.36 97.94 96.37 96.44 97.04 94.95 101.03 103.18 
SF-295   107.57 105.54 103.20 106.30 100.96 104.72 101.50 102.15 105.34 98.93 
SF-539   101.91 95.02 95.33 94.83 95.18 92.49 95.59 90.09 99.94 100.28 
SNB-19   101.93 96.85 98.84 99.91 100.32 98.00 100.88 96.23 102.55 100.74 
SNB-75   85.59 92.38 90.69 95.29 95.26 84.42 83.70 86.06 92.65 98.92 
U251   107.42 102.29 101.54 99.56 103.60 97.08 102.75 100.16 105.51 100.73 
Melanoma 
LOX IMVI   90.45 95.08 91.49 94.19 93.50 99.99 92.33 93.59 95.86 98.74 
MALME-3M    96.29 93.84 89.95 106.80 102.26 101.01 95.16 97.75 104.21 99.13 
M14   98.84 94.70 95.59 100.63 95.98 97.53 97.51 93.53 99.62 100.38 
MDA-MB-435  103.83 99.70 104.25 103.46 101.01 98.74 98.97 101.01 103.21 104.23 
SK-MEL-2   108.33 106.56 101.37 104.40 104.67 106.38 103.82 107.11 105.55 110.57 
SK-MEL-28   103.73 106.24 99.94 103.49 101.78 101.52 99.22 97.50 109.71 108.49 
SK-MEL-5   99.53 102.47 100.10 102.72 98.47 99.83 99.26 100.11 99.12 102.74 
UACC-257   105.90 103.90 108.36 99.26 104.79 102.16 97.53 104.60 110.64 106.40 
UACC-62   97.45 97.03 95.98 94.64 96.56 91.66 92.05 95.66 103.16 99.80 
Ovarian Cancer 
IGROV1   97.87 97.83 92.80 98.69 98.16 96.46 96.39 99.77 102.43 102.84 
OVCAR-3   106.25 100.96 102.85 106.62 105.95 102.98 101.46 106.39 107.34 103.94 
OVCAR-4   115.78 107.60 113.41 109.59 107.80 101.51 104.32 110.06 119.05 111.40 
OVCAR-5    96.32 100.71 100.30 100.63 97.59 92.94 94.71 94.98 103.00 102.53 
OVCAR-8   102.82 99.35 103.93 101.50 100.81 99.00 101.20 99.92 103.34 100.68 
NCI/ADR-RES  97.51 99.35 101.07 98.86 102.58 102.72 101.82 102.76 110.88 113.07 
SK-OV-3   104.58 104.43 96.62 104.08 102.49 94.52 105.26 104.42 111.76 116.42 
Renal Cancer 
786-0   106.47 103.33 102.09 102.05 100.61 103.81 100.98 102.57 105.53 106.21 
A498   121.94 118.17 121.98 123.86 113.91 110.84 113.12 110.32 133.78 120.25 
ACHN   101.88 104.48 101.69 104.48 103.60 104.51 98.83 98.25 102.54 107.16 
CAKI-1   84.79 88.92 86.14 91.11 89.17 86.56 91.02 80.65 90.12 93.18 
RXF 393   108.56 112.49 106.62 115.48 114.05 112.92 111.86 111.48 116.86 120.13 
SN12C    98.92 96.52 99.43 101.48 95.93 98.28 95.53 96.24 98.60 100.68 
TK-10   113.31 105.99 113.01 101.86 110.00 104.12 103.09 105.01 110.63 109.47 
UO-31   67.66 72.64 63.90 72.11 70.56 65.42 76.52 60.63 71.10 78.40 
Prostate Cancer 
PC-3   93.13 96.33 96.06 95.35 92.90 93.64 92.34 91.54 100.23 99.89 
DU-145   111.47 113.10 115.55 109.63 113.64 112.22 113.02 113.34 113.59 115.54 
Breast Cancer 
MCF7   96.27 97.85 96.02 97.69 95.19 96.70 96.21 93.41 100.10 99.86 
MDA-MB-231/ATCC  98.76 100.32 96.41 103.00 102.57 99.41 102.07 99.48 101.03 105.54 
HS 578T   108.55 108.86 104.42 106.06 102.15 100.28 101.96 95.63 114.64 115.46 
BT-549   102.49 105.74 104.06 103.83 101.49 95.56 100.00 97.41 106.65 108.30 
T-47D   113.29 110.14 104.84 92.51 107.08 102.66 109.76 104.88 112.33 106.17 




Cell Line                                                      Mean Growth percent 
   (5g) (5h) (5i) (5j) (5k) (5l) (5m) (4e) (4f) (4g) 
Leukemia 
CCRF-CEM     94.31 103.21     97.51 98.23 103.27 101.75 
HL-60(TB)    99.11 99.74 98.47` 100.66 98.02 101.23 99.70  98.34 98.93 99.51 
K-562   104.12 103.93 104.99 105.78 105.56 95.85 96.82 96.48 95.29 98.85 
MOLT-4   108.34 111.87 106.25 110.47 105.91 104.09 103.80 100.95 99.68 98.54 
RPMI-8226    104.54 106.26 100.16 112.34 104.63 96.62 102.50 99.53 93.11 97.25 
SR    101.36 99.99 120.31 109.76 104.29 105.22 103.17 94.89 104.41 111.04 
Non-Small Cell Lung Cancer 
A549/ATCC    105.93 103.95 108.71 98.41 106.72 102.46 102.18 97.48 103.88 101.17 
EKVX    104.27 103.35 102.71 100.77 112.00 91.74 88.53 91.54 95.17 98.33 
HOP-62    105.54 101.43 97.82 102.20 102.03  102.60 101.57 100.96 101.54 98.30 
HOP-92    105.06 118.78 116.47 108.77 114.16 104.21 95.43 105.77 97.29 107.01 
NCI-H226    104.34 105.35 101.81 105.86 109.40 96.98 95.26 100.31 101.15 103.12 
NCI-H23    105.52 105.48 99.85 109.59 105.16 105.61 102.10 99.90 102.60 106.38 
NCI-H460    107.25 105.63 103.16 103.18 104.11 104.74 105.75 107.45 105.82 105.78 
NCI-H522    93.26 89.66 102.21 93.85 94.89 96.39 92.78 96.03 89.87 88.08 
Colon Cancer 
COLO 205   110.95 111.65 108.56 108.64 110.11 109.39 109.65 111.96 110.29 108.49 
HCC-2998    106.55 113.26 107.61 115.63 106.47 107.29 105.71 103.44 102.96 102.81 
HCT-116    104.50 102.54 101.10 100.71 99.84 104.34 98.94 99.37 98.58 105.59 
HCT-15    106.72 104.12 107.45 107.89 108.52 104.12 105.45 106.83 105.48 111.03 
HT29    101.30 103.38 101.18 103.69 107.27 105.56 104.05 103.33 97.46 101.87 
KM12    106.26 103.28 104.51 108.56 106.14 101.87 104.75 104.02 106.66 102.60 
SW-620    104.82 104.87 96.41 99.91 98.28 96.43 102.44 113.32 103.63 107.05 
CNS Cancer 
SF-268    103.31 101.62 101.71 98.82 99.59 101.14 95.71 97.76 99.26 101.76 
SF-295    100.76 104.77 103.94 103.66 102.68 101.40 102.38 103.21 99.72 102.98 
SF-539    104.69 99.44 99.68 99.54 93.86 95.02 95.24 96.16 99.04 91.11 
SNB-19    97.68 101.99 99.23 102.36 100.52 99.31 96.42 97.94 96.77 100.85 
SNB-75    103.14` 93.60 103.43 100.70 97.45 94.47 76.55 78.19 99.84 91.98 
U251    100.53 102.07 103.67 97.83 103.10 97.24 107.80 98.86 99.01 98.25 
Melanoma  
LOX IMVI     97.94 93.71 95.65 96.57 96.23 95.99 90.93 96.03 92.68 94.20 
MALME-3M     99.85 101.71 114.08 101.03 93.12 97.63 95.06 88.20 92.67 103.64 
M14    100.73 103.47 99.89 102.00 100.69 98.08 97.11 98.20 98.86 105.43 
MDA-MB-435  108.58 110.06 105.18 105.12 105.95 104.77 101.67 100.23 107.46 106.13 
SK-MEL-2   104.43 102.08 105.35 105.29 107.25 108.78 103.27 107.61 100.06 103.68 
SK-MEL-28    104.05 108.09 101.02 102.99 104.67 103.65 103.85 101.86 98.83 102.58 
SK-MEL-5    101.24 104.06 97.36 99.49 99.06 100.48 96.50 101.60 99.58 101.33 
UACC-257    110.78 106.18 110.09 106.03 106.22 105.05 103.68 100.44 107.95 96.51 
UACC-62    100.27 99.47 100.10 98.08 99.38 99.59 96.85 97.75 96.60 93.07 
Ovarian Cancer 
IGROV1    101.04 96.59 96.77 97.28 96.33 100.17 94.30 98.11 96.16 99.00 
OVCAR-3    110.30 111.48 107.45 107.12 105.20 104.18 104.79 101.09 104.66 106.17 
OVCAR-4    120.33 115.56 113.29 109.05 112.32 113.16 111.58 101.15 116.91 108.48 
OVCAR-5     99.68 103.56 99.69 98.61 101.07 99.88 100.54 102.81 99.71 105.65 
OVCAR-8    103.60 101.27 100.37 100.31 101.49 100.26 103.81 95.96 100.60 96.69 
NCI/ADR-RES   112.36 109.24 107.51 106.55 110.90 105.22 103.52 99.85 102.68 104.22 
SK-OV-3    110.66 101.62 101.87 109.71 111.09 107.57 101.35 88.01 100.29 95.44 
Renal Cancer 
786-0    105.42 102.39 106.44 108.46 104.35 103.82 103.41 101.15 101.28 102.43 
A498    110.32 133.83 112.31 129.30 120.57 125.04 133.11 116.28 116.05 108.64 
ACHN    109.34 102.97 101.68 101.32 101.52 102.80 95.84 100.69 104.62 97.92 
CAKI-1    97.87 89.94 87.41 87.57 87.49 86.79 82.89 91.50 91.13 90.25 
RXF 393    120.16 120.33 116.15 113.61 116.09 118.26 111.59 121.19 110.15 114.54 
SN12C    105.48 101.85 98.28 98.53 100.47 100.05 94.62 97.59 102.37 99.36 
TK-10    109.50 107.37 113.43 102.57 106.34 107.85 112.36 104.28 104.84 97.87 
UO-31     76.30 66.75 67.01 65.95 67.06 70.22 62.14 73.14 70.06 74.23 
Prostate Cancer 
PC-3     98.03 95.55 97.94 96.31 96.70 93.25 93.11 97.59 95.10 97.74 
DU-145    118.63 112.98 118.79 117.27 118.08 115.86 112.86 111.69 113.78 113.66 
Breast Cancer 
MCF7     98.72 101.01 98.13 99.97 100.68 95.53 91.70 91.72 92.68 98.41 
MDA-MB-231/ATCC   102.30 101.55 105.44 98.88 104.61 102.09 94.79 101.18 92.55 97.17 
HS 578T    111.44 104.36 103.38 100.61 104.56 100.71 107.86 112.66 101.90 108.83 
BT-549    104.80 112.45 113.43 103.05 107.26 102.12 102.55 102.40 101.56 103.02 
T-47D    109.58 102.93 102.06 102.41 110.99 101.72 108.12 96.21 101.04 95.84 








Cell Line                                                      Mean Growth percent  
   (4h) (4i) (4j) (5n) 
Leukemia 
HL-60(TB)    97.87 99.08 97.93 97.71 
K-562    102.10 99.53 98.53 90.47 
MOLT-4    102.16 105.42 97.99 103.66 
RPMI-8226   95.18 91.94 93.08 85.17 
SR    114.45 108.71 110.71 95.98 
Non-Small Cell Lung Cancer 
A549/ATCC    104.79 98.45 104.05 101.19 
EKVX    101.87 84.66 111.43 86.44 
HOP-62   95.20 99.37 100.98 95.69 
HOP-92   107.23 99.12 102.94 93.26 
NCI-H226   97.30 101.06 102.80 102.58 
NCI-H23    95.32 101.68 103.71 101.15 
NCI-H460    100.80 102.45 102.23 102.78 
NCI-H522    97.44 91.71 95.93 94.81 
Colon Cancer 
COLO 205   113.25 109.71 111.72 103.98 
HCC-2998   101.16 107.87 101.80 105.81 
HCT-116   99.51 100.07 103.91 98.23 
HCT-15   103.83 109.02 110.83 102.67 
HT29   97.04 102.57 110.63 100.18 
KM12   105.31 107.15 103.27 100.12 
SW-620   95.36 97.67 99.37 98.97 
CNS Cancer 
SF-268   97.21 97.14 99.39 97.07 
SF-295   99.16 101.19 100.49 99.54 
SF-539   95.44 94.01 91.00 85.36 
SNB-19   95.37 97.51 95.88 95.16 
SNB-75   92.61 88.11 85.40 77.68 
U251   102.90 99.05 100.85 95.23 
Melanoma 
LOX IMVI   90.63 99.50 94.59 92.63 
MALME-3M   99.97 91.50 96.67 88.76 
M14   99.63 98.73 100.38 94.48 
MDA-MB-435  108.39 102.08 98.33 101.03 
SK-MEL-2   104.13 101.40 104.92 105.07 
SK-MEL-28   101.16 97.28 100.67 96.25 
SK-MEL-5   96.23 98.46 98.03 98.87 
UACC-257   103.57 97.50 100.77 102.65 
UACC-62   97.89 96.36 97.39 94.90 
Ovarian Cancer 
IGROV1   98.35 93.96 92.19 93.89 
OVCAR-3   103.29 103.28 101.00 100.93 
OVCAR-4   105.43 104.30 102.65 106.84 
OVCAR-5   98.74 97.12 97.91 95.07 
OVCAR-8   96.69 99.73 102.07 97.78 
NCI/ADR-RES  100.25 105.76 105.79 102.59 
SK-OV-3   98.41 99.72 99.74 97.89 
Renal Cancer 
786-0   104.23 106.42 104.17 100.57 
A498   108.24 108.28 112.09 120.55 
ACHN   99.70 99.30 97.58 95.73 
CAKI-1   88.09 93.08 86.72 77.29 
RXF 393   113.63 115.73 115.61 120.59 
SN12C   96.38 97.67 98.28 96.31 
TK-10   103.94 97.23 104.52 107.55 
UO-31   69.14 73.35 67.09 62.89 
Prostate Cancer 
PC-3   96.47 98.27 94.20 86.82 
DU-145   117.52 109.39 113.51 110.12 
Breast Cancer 
MCF7   92.22 94.50 95.18 90.31 
MDA-MB-231/ATCC  100.23 100.00 95.29 91.76 
HS 578T   98.60 99.89 95.72 97.09 
BT-549   103.74 97.64 101.87 97.06 
T-47D   103.07 96.21 103.96 94.81 





In silico ADME prediction 
The pharmacokinetics of the compounds under study, ADME predictions were done for the 
compounds using Qikprop v3.5 (Schrödinger, Inc., New York, NY, 2012).
5
 All the 
compounds prepared by LigPrep were used for the calculation of pharmacokinetic properties 
by QikProp. The program QikProp, utilizes the method of Jorgensen to compute 
pharmacokinetic properties and descriptors such as octanol/water partitioning coefficient, 
aqueous solubility, brain/blood partition coefficient, intestinal wall permeability, plasma 
protein binding and others. 
TableS2.Calculation of Lipinski’s ‘ruleof 5’parametersfor Benzothiazole-triazole hybrids 







(Molecule) Mol wt donor HB(<5) Accpt HB (<10) QP logPo/w (<5) Rule of five (<4) 
(4a) 393.419 0 7.25 2.819 0 
 (4b) 365.409 1 7.25 3.118 0 
 (4c) 379.436 1 7.25 3.534 0 
 (4d) 393.462 1 7.25 3.898 0 
 (4e) 393.419 0 7.25 2.738 0 
(4f) 407.446 0 7.25 3.104 0 
(4g) 410.406 0 6.25 3.088 0 
(4h) 444.305 1 7.25 3.681 0 
(4i) 390.419 0 6.75 2.995 0 
(4j) 393.419 0 7.25 2.379 0 
 (5a) 289.311 1 6.2 1.348 0 
 (5b) 335.383 1 6.5 2.976 0 
 (5c) 357.429 2 7.25 2.579 0 
 (5d) 353.373 1 6.5 3.208 0 
 (5e) 365.409 1 7.25 3.067 0 
 (5f) 299.35 1 6.5 2.275 0 
(5g) 341.43 1 6.5 3.155 0 
(5h) 360.392 0 6 2.576 0 
(5i) 349.409 1 6.5 3.279 0 
 (5j) 301.365 1 6.5 2.421 0 
(5k) 315.392 1 6.5 2.76 0 
 (5l) 329.419 1 6.5 3.094 0 
(5m) 343.446 1 6.5 3.022 0 































(4a) 80.36 115.33 -2.03 83.90 -0.156 -6.754 8 
(4b) 93.48 498.26 -1.17 396.68 0.023 -7.066 6 
(4c) 100.00 628.38 -1.09 553.86 0.178 -7.03 6 
(4d) 100.00 644.312 -1.166 568.357 0.29 -7.118 7 
 (4e) 82.395 159.323 -1.694 123.119 -0.236 -6.152 8 
 (4f) 85.26 174.83 -1.85 98.14 -0.043 -6.604 8 
 (4g) 80.00 89.92 -2.02 66.43 0.052 -6.341 8 
 (4h) 96.78 498.11 -1.02 1050.36 0.157 -6.986 6 
 (4i) 83.77 156.63 -1.77 120.95 -0.106 -6.5 8 
(4j) 79.702 147.672 -1.56 111.635 -0.349 -5.206 8 
(5a) 75.22 180.27 -1.47 100.38 -0.399 -5.143 6 
(5b) 95.50 719.50 -0.73 640.72 0.062 -6.672 3 
(5c) 88.43 390.52 -1.08 330.57 0.073 -5.723 4 
 (5d) 96.85 718.39 -0.62 1154.75 0.102 -6.547 3 
 (5e) 96.08 723.20 -0.82 644.07 0.063 -6.573 4 
 (5f) 92.43 821.13 -0.63 738.68 -0.15 -5.572 3 
(5g) 100.00 807.14 -0.69 724.64 0.219 -5.814 3 
(5h) 81.84 167.72 -1.32 130.28 -0.106 -5.344 5 
(5i) 100.00 717.60 -0.76 638.91 0.214 -6.584 3 
(5j) 92.27 721.27 -0.84 642.11 -0.159 -5.707 5 
(5k) 94.29 724.28 -0.93 644.64 -0.06 -5.862 6 
(5l) 95.08 622.87 -1.10 547.97 0.055 -6.02 7 
(5m) 94.52 612.34 -1.04 440.99 0.052 -4.929 8 
 (5n) 100.00 734.11 -0.94 654.31 0.436 -6.845 5 



















S4.Spectras 1Hand 13C: 
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